MBX Biosciences reported second quarter 2026 financial results, posting a net loss of $37.1 million on R&D expenses of $31.0 million and G&A expenses of $9.9 million. The company holds $418.6 million in cash and investments, sufficient to fund operations into 2029. Key operational updates include the initiation of recruitment for the Phase 3 oPTimize trial of canvuparatide for chronic hypoparathyroidism and preliminary Phase 1 data for MBX 4291 showing a mean weight loss of 7% at eight weeks. Additionally, MBX nominated MBX 6180 as its lead GLP-1/GIP/GCG triple agonist development candidate for obesity. Steve Hoerter was appointed Chairman and CEO, succeeding Kent Hawryluk, while John Smither became CFO. The company operates in the biopharmaceutical industry, developing precision peptide therapies for endocrine and metabolic disorders.

MBX Biosciences, Inc. announced the departure of CEO Kent P. Hawryluk effective July 13, 2026, and the appointment of Steven Hoerter as new President and CEO, effective the same date. John Smither was also appointed as Chief Financial Officer effective July 13, 2026. MBX Biosciences, Inc. is a biotechnology company focused on developing therapeutic solutions for rare diseases.

MBX Biosciences announced one-year data from Phase 2 Avail™ and open-label extension clinical trials for canvuparatide, a potential once-weekly PTH replacement therapy for chronic hypoparathyroidism. At the 12-week mark, 63% of canvuparatide-treated patients achieved the primary composite endpoint compared to 31% for placebo. One-year data showed a 57% responder rate among evaluable patients with no rescue therapy required in the final week. The drug demonstrated consistent pharmacokinetic profiles, improved kidney function via increased eGFR, and maintained serum calcium within normal ranges. The treatment was generally well tolerated with no treatment-related serious adverse events reported. MBX Biosciences is a biotechnology company developing therapies for endocrine disorders.